Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study
The Prostate ( IF 2.6 ) Pub Date : 2021-07-01 , DOI: 10.1002/pros.24187 Dong-Yi Chen, Po-Jung Su, Lai-Chu See, Jia-Rou Liu, Cheng-Keng Chuang, See-Tong Pang, Chi-Nan Tseng, Shao-Wei Chen, I-Chang Hsieh, Pao-Hsien Chu, Yung-Chang Lin, Cheng-Lung Hsu, John Wen-Cheng Chang, Miao-Sui Lin, Jong-Hwei S. Pang, Ming-Jer Hsieh, Wen-Kuan Huang
The Prostate ( IF 2.6 ) Pub Date : 2021-07-01 , DOI: 10.1002/pros.24187 Dong-Yi Chen, Po-Jung Su, Lai-Chu See, Jia-Rou Liu, Cheng-Keng Chuang, See-Tong Pang, Chi-Nan Tseng, Shao-Wei Chen, I-Chang Hsieh, Pao-Hsien Chu, Yung-Chang Lin, Cheng-Lung Hsu, John Wen-Cheng Chang, Miao-Sui Lin, Jong-Hwei S. Pang, Ming-Jer Hsieh, Wen-Kuan Huang
We aimed to determine whether cardiovascular (CV) risk in patients with prostate cancer (PCa) differs between those who receive gonadotropin-releasing hormone (GnRH) agonist (GnRHa) therapy and those who receive GnRH antagonist therapy.
中文翻译：
与促性腺激素释放激素激动剂相比，促性腺激素释放激素拮抗剂在前列腺癌中的心血管风险较低：一项全国性队列和体外研究
我们旨在确定接受促性腺激素释放激素 (GnRH) 激动剂 (GnRHa) 治疗和接受 GnRH 拮抗剂治疗的前列腺癌 (PCa) 患者的心血管 (CV) 风险是否存在差异。
更新日期：2021-07-20
中文翻译：
与促性腺激素释放激素激动剂相比，促性腺激素释放激素拮抗剂在前列腺癌中的心血管风险较低：一项全国性队列和体外研究
我们旨在确定接受促性腺激素释放激素 (GnRH) 激动剂 (GnRHa) 治疗和接受 GnRH 拮抗剂治疗的前列腺癌 (PCa) 患者的心血管 (CV) 风险是否存在差异。
京公网安备 11010802027423号